ArticlePloS one2022

Effectiveness and safety of weekly paclitaxel and cetuximab as a salvage chemotherapy following immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: A multicenter clinical study.

Takahiro Wakasaki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.